Copyright
©2009 The WJG Press and Baishideng.
World J Gastroenterol. Jan 28, 2009; 15(4): 449-456
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Published online Jan 28, 2009. doi: 10.3748/wjg.15.449
Table 1 Patient characteristics
| Treatment group | ||
| CAPIRI | CAPIRI-Bev | |
| N (%) | 17 (37%) | 29 (63%) |
| Age (median), years (range) | 66 (55-81) | 60 (37-80) |
| Gender, M/F | 9/8 | 22/7 |
| Site of primary tumor, n (%) | ||
| Rectum | 7 (41.2) | 15 (51.7) |
| Colon | 10 (58.8) | 14 (48.2) |
| Site of metastases, n (%)1 | ||
| Hepatic | 12 (71) | 24 (83) |
| Pulmonary | 6 (35) | 11 (38) |
| Lymphatic and nodal | 4 (24) | 17 (59) |
| Skeletal | 1 (6) | 4 (14) |
| Peritoneal | 1 (6) | 5 (17) |
| Other sites | 6 (35) | 5 (17) |
| Performance status (Karnofsky) | ||
| 100% | 4 (23.5) | 17 (58.6) |
| 90% | 1 (5.9) | 5 (17.2) |
| 85% | 1 (5.9) | 0 (0) |
| 80% | 2 (11.8) | 3 (10.3) |
| 70% | 4 (23.5) | 0 (0) |
| Adjuvant chemotherapy received | 8 (47%) | 8 (27.6%) |
- Citation: Moehler M, Sprinzl MF, Abdelfattah M, Schimanski CC, Adami B, Godderz W, Majer K, Flieger D, Teufel A, Siebler J, Hoehler T, Galle PR, Kanzler S. Capecitabine and irinotecan with and without bevacizumab for advanced colorectal cancer patients. World J Gastroenterol 2009; 15(4): 449-456
- URL: https://www.wjgnet.com/1007-9327/full/v15/i4/449.htm
- DOI: https://dx.doi.org/10.3748/wjg.15.449